Navigation Links
Personalised Medicine: An Opportunity for Investment
Date:1/14/2009

LONDON, Jan. 14 /PRNewswire/ -- The pharmaceutical industry is currently facing some key challenges. The increase in drug development costs, a decrease in the number of drugs being approved, and scrutiny from regulatory authorities are forcing companies to look at alternative revenue generators. Patients themselves are also demanding more effective and safer drugs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Pharmacogenomics therefore presents a convincing alternative to guide drug development and therapy. Pharmacogenomics deals with the influence of genetic variations on drug response in patients by correlating gene expression with a drug's efficacy. Personalised medicine is the result of individualised pharmacotherapy, which allows the formulation of drugs that offer appropriate treatment to the right person as needed.

"Recent reports of mishaps taking place due to improper drug metabolism, even when taken at optimal dose, have forced companies to consider individualised medicine more of a necessity than a mere research project," notes Frost & Sullivan (http://www.drugdiscovery.frost.com) Research Analyst Prabakar Sampath. "Every year several hundreds of patients either do not benefit from the treatment they are provided or develop adverse reactions to it. These are compelling reasons enough to pursue personalised medicine as a future directive."

Critics of personalised medicine often suggest that interest in research for a given pharmacogenomics study would decrease because it would only serve a niche market. They contend that a personalised approach would reduce new patient trials for some therapies.

However, a reduction in initial sales will be compensated by greater compliance, leading to higher product use.
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention
2. U.S. Preventive Medicine: Knowing Risk Factors & Early Detection are Best Strategies for Colon Cancer Prevention
3. Personalizing medicine: New research shows potential of targeted therapies for cancer
4. Measuring medicine: How new technologies could help doctors predict patient outcomes
5. The Changing Face of Medicine: National Medical Fellowships Annual Awards Gala Honors Three Fellows
6. Florida and California Represent Equivalent Areas of Opportunity in the Alzheimers Disease Drug Market
7. Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials'
8. Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity
9. ECPI College of Technology and Medical Careers Institute Announce Extension for South Carolina Military Scholarship Opportunity
10. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
11. HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2009 Out-of-Pocket Drug Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... On May 21, 2015, Elle Magazine in article titled ... Botox ?” reported on the four most commonly searched beauty ... to determine these results and then sought expert help to ... example, is how to keep neck skin tight . ... the appropriate age to start receiving Botox injections . ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Johnson ... reached a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... gynecomastia due to his use of the antipsychotic ... been selected for the third bellwether trial to ... tort litigation underway in Pennsylvania’s Philadelphia Court of ...
(Date:5/29/2015)... 2015 Intermountain Healthcare of ... Stratus Video Interpreting for on-demand ... communication and timely care for patients with ... Stratus’ video remote interpreting (VRI) services will ... to quickly access qualified medical interpretation in ...
Breaking Medicine News(10 mins):Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4
... National ... Immunization Awareness Month, NORTH HAVEN, Conn., Sept. 6 In ... in,Connecticut is reminding parents to make sure their adolescents,immunizations are up ... the perfect time for parents to check with their child,s provider,to ...
... Hospital Directory show new rules issued by the Centers, for ... rural hospitals and hospitals specializing in cardiac care. ... changes in outlier payment are also forecasted., ... Services (CMS) has issued the most sweeping rule,changes for hospital ...
... IV product a proven treatment -, BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, today ... to Australia in order to be able to ... that continent,s equine influenza outbreak.,The outbreak began in ...
... of women with breast cancer stopped taking a commonly ... to a new study from researchers at the University ... the study were taking aromatase inhibitors, a type of ... fuels some breast cancers. The treatment is generally given ...
... LOUISVILLE, Ky., Sept. 5 Ventas, Inc. (NYSE:,VTR) ("Ventas" ... Directors,declared a regular quarterly dividend of $0.475 per share, ... record on September 17, 2007. The,dividend is the third ... dividend. Ventas, Inc. is a leading healthcare real ...
... a,wholly owned subsidiary of Siemens Corporation, announced today that ... offer for all outstanding,shares of common stock of Dade ... has been extended to 12:00 Midnight, New York City ... being made pursuant to,an Agreement and Plan of Merger, ...
Cached Medicine News:Health News:Immunizations Part of Back to School Preparations 2Health News:Immunizations Part of Back to School Preparations 3Health News:Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations 2Health News:Bioniche Responds to Australian Equine Influenza Outbreak 2Health News:Bioniche Responds to Australian Equine Influenza Outbreak 3Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 2Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 4Health News:Siemens Extends Tender Offer for Acquisition of Dade Behring 2
(Date:5/29/2015)... 2015  Fair Rate Funding, a leader in TV ... Delaware found Thursday that Boston ... pelvic organ prolapse (POP) and Stress Urinary Incontinence (SUI) ... hid the design flaws from the plaintiff, Deborah ... Transvaginal mesh, also known as TV ...
(Date:5/29/2015)... May 29, 2015  Dr. Yair Walzer has ... vaginal health issues often caused by menopause. The MonaLisa Touch™, ... anesthesia, received FDA clearance in 2014. Dr. Walzer is one ... to offer the special fractional CO 2 laser specifically ... survivors. In 2010 there were greater than ...
(Date:5/29/2015)... Massachusetts and SPARTANBURG, South Carolina ... The Guardian Research Network and Molecular Health have announced ... and molecular diagnostic decision support to the majority of ... Guardian Research Network will collaborate with Molecular Health to ... testing to identify cohorts from hundreds of thousands of ...
Breaking Medicine Technology:TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict. 2TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict. 3The Newest FDA-Cleared Breakthrough In Women's Health Treatments 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4
... Conatus Pharmaceuticals Inc. today announced the closing of ... financing.  This financing was led by new investor, AgeChem ... existing investors; Aberdare Ventures, Advent Venture Partners, Bay City ... will use the proceeds to advance the clinical development ...
... Mindray Medical International Limited (NYSE: MR), a leading developer, ... that it will report its financial results for the ... market closes on February 28, 2011. Mindray,s management will ... March 1, 2011 U.S. Eastern Time (9:00 PM on ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Mindray to Report Fourth Quarter and Full Year 2010 Financial Results on February 28, 2011 2
... patented Miami J® collar is designed to ... patient. Break-through fabrics inhibit decubitus during long-term ... and speed recovery. And the unique ... any prefabricated extended wear collar. And kids ...
One-piece rigid cervical collar is designed to fit securely around the neck and mandible to provide immobilization and support of the cervical region...
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
... Orthosis ensures comfort and immobilization ... anterior frame and occipital component. ... flow and easy application. Large ... For added comfort, removable, flannel-covered, ...
Medicine Products: